NASDAQ · DVAX
Healthcare · Drug Manufacturers - Specialty & Generic
$15.50
Up+$0.00 (+0.00%)
Updated Sep 11, 2026, 5:06 AM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
DVAX does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning DVAX.
DVAX research
Company profile and research snapshot.
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 24, 2025 | William Blair | Market Perform | — |
| Aug 22, 2025 | JMP Securities | Market Outperform | — |
| Aug 8, 2025 | JMP Securities | Market Outperform | — |
| May 7, 2025 | JMP Securities | Market Outperform | — |
| Apr 17, 2025 | Goldman Sachs | Sell | — |
No generated briefing is available yet.
Benzinga · Feb 4, 2026
https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20260204-1482028/1482028_day5dvax6.pdf
defenseworld.net · Nov 29, 2025
Geode Capital Management LLC lowered its holdings in Dynavax Technologies Corporation (NASDAQ: DVAX) by 12.3% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,688,774 shares of the biopharmaceutical company's stock after selling 377,048 shares during the quarter. Geode Capital Management
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning DVAX.
